QPPV.COM KNOWLEDGE ASSESSMENT

Delandistrogene Moxeparvovec: Gene Therapy Evidence, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Delandistrogene Moxeparvovec: Micro-Dystrophin Gene Therapy and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should orphan-drug and fast-track designations be presented in an evidence assessment?

As independent confirmation that the product is clinically effective. As development or regulatory-status designations, not as independent evidence of efficacy. As proof that the EMA has granted a marketing authorisation. As substitutes for evaluating controlled trial results.

Question 2 of 10 Why did the FDA require a prospective observational postmarketing study after the liver-safety action?

To replace all spontaneous reporting, which is no longer relevant after approval. Because spontaneous reports alone were considered insufficient to assess the serious liver risk, and prospective follow-up can add structured patient-level data. To prove that every elevated liver enzyme is caused by the gene therapy. To determine whether the EU should grant an authorisation.

Question 3 of 10 A patient with pre-existing hepatic disease is being considered for treatment. Which pharmacovigilance interpretation is best supported by the article?

Baseline hepatic status is immaterial because the product is administered only once. Pre-existing hepatic impairment may increase risk and should be documented and assessed against current label restrictions. A normal platelet count is sufficient to exclude treatment-related liver risk. Only liver tests collected after the first eight weeks are relevant.

Question 4 of 10 A patient develops measurable micro-dystrophin expression after treatment. Which interpretation is most appropriate when assessing clinical benefit?

Expression confirms restoration of full-length dystrophin and predicts durable functional improvement. Expression demonstrates biological activity, but does not by itself establish the magnitude or durability of clinical benefit. Expression is equivalent to a statistically significant improvement in the trial's primary functional endpoint. Expression rules out disease progression as an explanation for later functional decline.

Question 5 of 10 Which conclusion best reflects the week-52 primary result from the phase 3 EMBARK trial?

The primary NSAA endpoint was statistically significant because several secondary measures favoured treatment. The primary NSAA endpoint was not statistically significant; favourable secondary measures do not change that primary-endpoint result. The trial established clinical benefit because micro-dystrophin expression was observed in treated participants. The primary endpoint was not assessable because the trial did not include a placebo group.

Question 6 of 10 Which statement best describes the evidentiary meaning of the FDA's 2023 accelerated approval?

It established that micro-dystrophin expression had been proven to predict clinical benefit in all DMD populations. It was a regulatory decision for a defined ambulatory population based on a surrogate endpoint considered reasonably likely to predict benefit, despite documented uncertainty. It was a traditional approval based on a statistically significant primary endpoint in EMBARK. It automatically granted marketing authorisation in the European Union.

Question 7 of 10 A patient experiences functional decline several months after treatment. Which case-assessment approach best reflects the article?

Attribute the decline to gene-therapy toxicity because it occurred after infusion. Attribute the decline to DMD progression because the underlying disease is progressive. Assess the timeline and clinical evidence while considering DMD progression, treatment-emergent toxicity, infection, concomitant treatment and measurement variability. Exclude the event from safety review unless a laboratory abnormality is also present.

Question 8 of 10 Which cardiac monitoring approach is described in the current US label summarized by the article?

Baseline troponin-I and weekly monitoring during the first month, with further assessment if clinically indicated. Troponin-I testing only when a patient reports chest pain. Daily electrocardiography for six months, with no biomarker monitoring. No cardiac monitoring is needed because DMD does not affect the heart.

Question 9 of 10 Which combination of information best supports long-term product-level safety assessment?

Patient identity alone and the date of the most recent clinic visit. A linked record of eligibility and genotype, product and lot, infusion details, baseline status, laboratory results, clinical events and longitudinal outcomes. The infusion dose and company name, without patient follow-up. Trial efficacy results without individual exposure or safety data.

Question 10 of 10 In phase 2 Study 102, the biological endpoint was met but the primary NSAA endpoint was not statistically significant in the full randomised population. What is the most appropriate interpretation?

Meeting the biological endpoint establishes that the treatment improved motor function in the full study population. The findings support transgene expression, while the non-significant primary functional result limits the conclusion about comparative clinical benefit. Exploratory subgroup results supersede the full-population primary analysis when baseline function is imbalanced. The study provides no relevant evidence because only a phase 3 trial can measure transgene expression.

Delandistrogene Moxeparvovec: Gene Therapy Evidence, Safety and Pharmacovigilance

Cookie Settings